5US FDA, FDA approval letter [EB/OL]. [2008-08-10]. http://www.fda.gov/cder/foi/appletter/2008/022156s0001tr. pdf.
6Varon J. Treatment of acute severe hypertension: current and newer agents [J]. Drugs, 2008, 68 (3) : 283-297.
7Andersson KH, Nordlander M, Westerlund RC. Preparation of short-acting 2,6-dimethyl-4-phenyl-l,4-dihydropyridine- 3,5-dicarboxylate calcium antagonist antihypertensives: WO, 9512578 [P]. 1995-05-11. (CA 1995, 123: 313768).
8Kosugi Y, Hori M, Nagasaka T. Synthesis of optically pure 1,4-dihydropyridine derivatives by means of diastereoisomeric separation of the hantzsch intermediates bearing (R)-l-phenylethylamino group [J]. Heterocycles, 1994, 39 (2): 591-602.
9Mattson A, Svensson C, Thornblom K, et al. Manufacture of clevidipine from 4- (2,3-dichlorophenyl) -1,4-dihydro-5- methoxycarbonyl-2,6-dimethyl-3-pyridinecarboxylic acid: WO, 2000031035 [P]. 2000-06-02. (CA2000, 133: 6161).
10Che D, Guntoori BR, Murthy KKS. Process to prepare 1,4-dihydropyridine intermediates and derivatives thereof: US, 20040204604 [P]. 2004-10-14.
